Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-l. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (Toronto:RVX.TO - News). For further information please visit www.resverlogix.com.

Contact Information

#202 - 279 Midpark Way SE
Calgary, AB T2X1M2

tel: 403.254.9252
fax: 403.256.8495


Investor Relations

Manager, Investor Relations
Sarah Zapotichny
tel: 403-254-9252
fax: 403-256-8495
e-mail: Sarah@resverlogix.com


Exchange: TSX
Industry: Biotechnology Research &/or Development
Market Cap: $190M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.